Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mathieu

Showing results (311-320 of 414) with videos related to

Pageof 42
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2003
Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasisJ-P Travagli, D Atallah, M-C Mathieu, et al.
Diabetes Technology & Therapeutics|September 24, 2009
A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trialC Mathieu, R Cuddihy, R F Arakaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 1996
The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter propertiesC S Zent, C Mathieu, D F Claxton, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 20, 2013
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trialH W Rodbard, B Cariou, B Zinman, et al.
Current Medicinal Chemistry|July 14, 2007
Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logsG Eelen, C Gysemans, L Verlinden, et al.
Diabetes, Obesity & Metabolism|July 8, 2016
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetesC Mathieu, M Herrera Marmolejo, J G González González, et al.
Clinical and Experimental Immunology|December 1, 1988
Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic proteinG Torpier, J F Colombel, C Mathieu-Chandelier, et al.
Pharmaceutical Research|February 1, 1997
Formulation of a charcoal suspension for intratumor injection. Part 1: Study of the nature, granulometry, and concentrationL Bonhomme-Faivre, M C Mathieu, J L Grossiord, et al.
Diabetes, Obesity & Metabolism|November 8, 2012
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trialsR E Ratner, S C L Gough, C Mathieu, et al.
Diabetologia|June 9, 2004
Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cellsB Movahedi, M Van de Casteele, N Caluwé, et al.
Pageof 42

Showing results (311-320 of 414) with videos related to

Sort By:
Pageof 42
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2003
Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasisJ-P Travagli, D Atallah, M-C Mathieu, et al.
Diabetes Technology & Therapeutics|September 24, 2009
A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trialC Mathieu, R Cuddihy, R F Arakaki, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 1996
The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter propertiesC S Zent, C Mathieu, D F Claxton, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 20, 2013
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trialH W Rodbard, B Cariou, B Zinman, et al.
Current Medicinal Chemistry|July 14, 2007
Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logsG Eelen, C Gysemans, L Verlinden, et al.
Diabetes, Obesity & Metabolism|July 8, 2016
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetesC Mathieu, M Herrera Marmolejo, J G González González, et al.
Clinical and Experimental Immunology|December 1, 1988
Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic proteinG Torpier, J F Colombel, C Mathieu-Chandelier, et al.
Pharmaceutical Research|February 1, 1997
Formulation of a charcoal suspension for intratumor injection. Part 1: Study of the nature, granulometry, and concentrationL Bonhomme-Faivre, M C Mathieu, J L Grossiord, et al.
Diabetes, Obesity & Metabolism|November 8, 2012
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trialsR E Ratner, S C L Gough, C Mathieu, et al.
Diabetologia|June 9, 2004
Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cellsB Movahedi, M Van de Casteele, N Caluwé, et al.
Pageof 42